China Pharma Holding (STU:XQJ) LT-Debt-to-Total-Asset : 0.10 (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is China Pharma Holding LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China Pharma Holding's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.10.

China Pharma Holding's long-term debt to total assets ratio increased from Jun. 2023 (0.01) to Jun. 2024 (0.10). It may suggest that China Pharma Holding is progressively becoming more dependent on debt to grow their business.

China Pharma Holding LT-Debt-to-Total-Asset Historical Data

The historical data trend for China Pharma Holding's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding LT-Debt-to-Total-Asset Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.10

0.04

0.23

0.09

China Pharma Holding Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.10	0.09	0.09	0.10

China Pharma Holding LT-Debt-to-Total-Asset Calculation

China Pharma Holding's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.331	/	15.102
	=	0.09

China Pharma Holding's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	1.303	/	13.248
	=	0.10

China Pharma Holding (STU:XQJ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China Pharma Holding LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (STU:XQJ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

China Pharma Holding Headlines

No Headlines